InvestSMART
  1. Home
  2. Research & Advice
  3. Research Tools
  4. Shares
  5. Global X S&P Biotech ETF (CURE)
  6. Company Announcements

Global X S&P Biotech ETF (ASX: CURE) - Announcements

Current share price for CURE : $52.550 0.11 (0.21%)+

Global X S&P Biotech ETF (CURE) is an Exchange Traded Fund - commonly known as an ETF. For more details about how ETFs work, feel free to check out our What is an ETF? overview. Global X S&P Biotech ETF (CURE, formerly ETFS S&P Biotech ETF) is an exchange traded fund that provides exposure to U.S. healthcare biotechnology companies. These companies are engaged in the research, development and manufacturing of products based on genetic analysis and genetic engineering.

Latest company announcements for Global X S&P Biotech ETF (CURE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$41 Global X Units on Issue June 2023 11 Jul 2023 10:31AM $42.930 $52.550 risen by 22.41%
$41 Global X Final Distribution Announcement - June 2023 4 Jul 2023 4:29PM $42.570 $52.550 risen by 23.44%
$41 Global X Estimated Distribution Announcement - June 2023 30 Jun 2023 8:38AM $43.500 $52.550 risen by 20.80%
$41 Global X Estimated Distribution Announcement - June 2023 26 Jun 2023 6:03PM $43.480 $52.550 risen by 20.86%
$41 Global X Units on Issue May 2023 5 Jun 2023 10:52AM $45.230 $52.550 risen by 16.18%
$41 Global X Units on Issue April 2023 5 May 2023 9:45AM $42.530 $52.550 risen by 23.56%
$41 Global X Units on Issue March 2023 5 Apr 2023 9:24AM $38.210 $52.550 risen by 37.53%
$41 CURE Half Year Accounts 15 Mar 2023 8:51AM $40.540 $52.550 risen by 29.63%
$41 Global X Units on Issue February 2023 6 Mar 2023 2:13PM $42.490 $52.550 risen by 23.68%
$41 Global X Units on Issue January 2023 2 Feb 2023 11:30AM $43.010 $52.550 risen by 22.18%
$41 Global X Units on Issue December 2022 4 Jan 2023 11:44AM $41.800 $52.550 risen by 25.72%
$41 Global X Units on Issue November 2022 1 Dec 2022 3:49PM $42.220 $52.550 risen by 24.47%
$41 Global X Units on Issue October 2022 7 Nov 2022 5:28PM $42.520 $52.550 risen by 23.59%
$41 PDS dated 25 October 2022 26 Oct 2022 1:28PM $43.300 $52.550 risen by 21.36%
$41 Global X Units on Issue September 2022 4 Oct 2022 4:22PM $42.570 $52.550 risen by 23.44%
$41 CURE Annual Financial Report 29 Sep 2022 1:21PM $42.640 $52.550 risen by 23.24%
$41 Change of Company Name 16 Sep 2022 2:04PM $43.560 $52.550 risen by 20.64%
$41 Replacement PDS dated 16 September 2022 16 Sep 2022 1:37PM $43.560 $52.550 risen by 20.64%
$41 ETFS Units on Issue August 2022 5 Sep 2022 12:35PM $42.320 $52.550 risen by 24.17%
$41 ETFS Units on Issue July 2022 2 Aug 2022 6:59PM $38.700 $52.550 risen by 35.79%
$41 Update - Dividend/Distribution 1 Jul 2022 6:50PM $36.530 $52.550 risen by 43.85%
$41 ETFS Units on Issue June 2022 1 Jul 2022 6:01PM $36.530 $52.550 risen by 43.85%
$41 Updated Estimated Distribution Announcement - Jun 2022 30 Jun 2022 9:52AM $36.920 $52.550 risen by 42.33%
$41 Estimated Distribution Announcement - June 2022 24 Jun 2022 5:11PM $38.030 $52.550 risen by 38.18%
$41 Change of ownership and control of responsible entity 15 Jun 2022 12:21PM $31.680 $52.550 risen by 65.88%

26 - 50 of 95 results

Page 2 of 4

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.